Published in Pharma Investments, Ventures and Law Weekly, March 25th, 2012
"We are pleased that we have eliminated this substantial obligation and the associated potential dilution," said Geert Kersten, Chief Executive Officer of CEL-SCI. "Our money is now being allocated to the greatest benefit of our shareholders,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly